Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 143,321 | 12,556 | -1,636 | 227,444 | 10,892 |
| Depreciation Amortization | 53,220 | 23,252 | 22,563 | 12,901 | 6,351 |
| Income taxes - deferred | 29,739 | 44,518 | 10,697 | -192,132 | 410 |
| Accounts receivable | -29,544 | -8,358 | -8,525 | 6,489 | -10,412 |
| Other Working Capital | -37,476 | -11,374 | -12,705 | 821 | -10,949 |
| Other Operating Activity | 34,799 | 27,976 | 50,339 | -13,796 | 24,274 |
| Operating Cash Flow | $194,059 | $88,570 | $60,733 | $41,727 | $20,566 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -409,440 | -57,624 | -20,968 | -92,752 | 2,342 |
| PPE Investments | -887 | -2,156 | -1,850 | -93 | -6 |
| Net Acquisitions | -5,856 | -26,653 | -93,202 | -9,247 | N/A |
| Purchase Of Investment | N/A | N/A | -1,000 | N/A | N/A |
| Purchase Sale Intangibles | -10,000 | 7,054 | -17,695 | -4,030 | -1,000 |
| Other Investing Activity | -7,086 | 7,254 | -17,395 | -10,770 | -4,363 |
| Investing Cash Flow | $-423,269 | $-79,179 | $-134,415 | $-112,862 | $-2,027 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,189,559 | N/A | N/A | N/A | 245,000 |
| Debt Repayment | -657,255 | N/A | N/A | N/A | -9,366 |
| Common Stock Issued | 110,183 | 4,517 | 6,415 | 8,849 | 16,199 |
| Common Stock Repurchased | -152,962 | -1,966 | -3,901 | -489 | -67,954 |
| Other Financing Activity | -160,940 | -10,074 | -7,508 | 0 | -53,854 |
| Financing Cash Flow | $328,585 | $-7,523 | $-4,994 | $8,360 | $130,025 |
| Exchange Rate Effect | -215 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 20,620 | 18,752 | 97,428 | 160,203 | 11,639 |
| End Cash Position | 119,780 | 20,620 | 18,752 | 97,428 | 160,203 |
| Net Cash Flow | $99,160 | $1,868 | $-78,676 | $-62,775 | $148,564 |
| Free Cash Flow | |||||
| Operating Cash Flow | 194,059 | 88,570 | 60,733 | 41,727 | 20,566 |
| Capital Expenditure | -887 | -2,156 | -1,850 | -93 | -6 |
| Free Cash Flow | 193,172 | 86,414 | 58,883 | 41,634 | 20,560 |